Home Companies Natco Pharma Q3 net down 26% to Rs 159 cr on flat revenue, fall in margins

Natco Pharma Q3 net down 26% to Rs 159 cr on flat revenue, fall in margins

06:13

Margin reduction of Oseltamivir in the US market cited as the major cause for the decline in profits during the quarter

from Companies http://bit.ly/2WQMq4C

No comments:

Subscribe to: Post Comments ( Atom )